What is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded in the mitochondrial genome — one of the few known peptides of mitochondrial origin. It was discovered in 2015 by Pinchas Cohen and his team at USC, published in Cell Metabolism.
Its discovery was significant because it demonstrated that mitochondria are not simply “energy factories” but also produce hormonal signals that regulate systemic metabolism. MOTS-c acts as a mitochondrial hormone that communicates the cell’s energy status to the rest of the organism.
Mechanism of action
AMPK activation (AMP-activated protein kinase):
- AMPK is the cellular “energy sensor.” When energy is low, AMPK activates and improves glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
- MOTS-c activates AMPK in a manner similar to physical exercise or metformin.
- This explains why it is called an “exercise mimetic”: it produces metabolic adaptations similar to training without the physical stress.
Insulin sensitivity:
- Studies in mice with high-fat diet-induced insulin resistance showed that MOTS-c restored insulin sensitivity to levels comparable to young animals.
- Mechanism: Inhibits the folate-dependent PPAR-γ pathway, reducing hepatic glucose production.
Effects on aging:
- Old mice (20 months) that received MOTS-c showed improvements in physical activity, body composition, and metabolic markers comparable to young mice.
- An active hypothesis is that MOTS-c helps explain why physical exercise extends life — the peptide could be one of the molecular mediators of those benefits.
MOTS-c and human aging
A study in Japanese centenarians (2019, PNAS) found genetic variants in the MOTS-c gene associated with exceptional longevity, suggesting that higher levels or more efficient MOTS-c function may contribute to longer lives.
Circulating MOTS-c levels also decline with age in humans, correlating with the loss of metabolic function associated with aging.
Clinical research status
As of 2025, MOTS-c is in Phase 1 studies for safety in humans. Preclinical trials in primates and rodents are promising, but controlled data in humans are very limited.
Very early stage research. For research use only. Human data are minimal. No approved protocol exists. For educational reference only.
Reported protocol (research reference)
| Vial sizes | 5 mg, 10 mg |
|---|---|
| Reported dose | In preclinical trials: 0.5–5 mg/kg in mice. Reported human research use: 5–10 mg subcutaneous several times per week. No approved protocol. |
| Half-life | Very limited data in humans. |
| FDA status | Not FDA approved |